Clinical study of CT-guided radiofrequency ablation plus intratumoral chemotherapy for patients with stage Ⅲ non-small cell lung cancer
10.3760/cma.j.issn.1673-422X.2018.02.003
- VernacularTitle:CT引导射频消融同期瘤内化疗治疗Ⅲ期非小细胞肺癌的临床研究
- Author:
Yonggang ZHU
1
;
Bin LU
;
Chengwei ZHOU
;
Weijun ZHAO
;
Xiaodong ZHAO
Author Information
1. 315020,宁波大学医学院附属医院胸外科
- Keywords:
Carcinoma,non-small-cell lung;
Catheter ablation;
Lobaplatin;
Intratumoral chemotherapy
- From:
Journal of International Oncology
2018;45(2):73-76
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy and safety of CT-guided radiofrequency ablation plus intratumoral chemotherapy in patients with stage Ⅲ non-small cell lung cancer (NSCLC).Methods From February 2014 to May 2015,38 patients with stage Ⅲ NSCLC who did not receive systematic chemotherapy due to advanced age were selected in our hospital.The patients were divided into experimental group (n =19) and control group (n =19) by stratified random method.The patients in experimental group received CT-guided radiofrequency ablation plus Lobaplatin intratumoral chemotherapy,and the patients in control group only received CT-guided radiofrequency ablation.The adverse events,Karnofsky performance system (KPS) scores,1-year overall survival rates and short-term curative effects of patients in the two groups were observed.Results All 38 patients completed the course of therapy successfully.The 3-month response rates and 6-month response rates in experimental group and control group were 89.5％ vs.63.2％ and 78.9％ vs.52.6％,with no significant differences (P =0.124;P =0.170).The KPS score improvement rates were 42.1％ (8/19) and 31.6％ (6/19) in experimental group and control group,the KPS score stable rates were 52.6％ (10/19) and 52.6％ (10/19) in the two groups,and the KPS score deterioration rates were 5.3％ (1/19) and 15.8％ (3/19) in the two groups,with no significant differences (P =0.737;P =1.000;P =0.290).The 1-year survival rate of patients in experimental group was higher than that in control group (89.5％ vs.73.7％),with a significant difference (x2 =5.573,P =0.034).The rates of less than or equal to grade 3 pain (31.6％ vs.42.1％),low fever (21.1％ vs.26.3％),aerothorax (31.6％ vs.42.1％),gastrointestinal reaction (15.8％ vs.31.6％) and bone marrow depression (5.3％ vs.15.8％) in experimental group were lower than those in control group,but the differences were not statistically significant (P =0.501;P =0.703;P =0.501;P =0.252;P =0.290).Conclusion CT-gnided radiofrequency ablation plus intratumoral chemotherapy for stage Ⅲ NSCLC can improve short-term survival rate,and it does not increase the adverse reaction.While,the long-term overall survival rate has yet to be followed up.
